Track market-moving stories before they get noisy

Aptos [APT] rebounded by over 13% in 24 hours as the wider market recovered. Altcoins took the lead on this recovery as the total market cap of all cryptos surpassed $2.77 trillion, up by more than 2.21%.

At the time of writing, APT’s daily trading volume was $100 million, primarily driven by the hype around the upgrade of the ecosystem. What are the final details of the update though?

Aptos Labs announces upgrade as network reacts
Aptos Labs announced the upgrade of Block-STM, which has been running in parallel on Aptos since the mainnet. This upgrade was completed on 15th October and was named Block-STM v2, with other chains building on it.

This upgrade has since increased transaction throughput and scalability. In fact, this process was explained by Aptos Labs’ Head of Research Alexander Spiegelman and Near Protocol [NEAR] co-founder Illia Polosukhin.

Source: Aptos/X
As a result, the throughput and network activity responded instantly. For instance, the chain’s TPS hit a peak value of 1,308 while the real-time throughput was 174. This revealed that there was a difference between the theoretical and real values.

Additionally, Daily Active Accounts rose from 46,670 to 49,385, a 5.82% uptick.

As a result, the monthly total of active accounts hit a peak of 710,712, with still 16 days to go before the end of October. New Accounts Created also grew from 4,098 to 4,395.

Source: Aptos Labs Explorer
User transactions also followed suit with a rise of more than 1.335 million in a single day. That is, 9.575 million transactions compared to 10.91 million the following day.

Why are bulls struggling to break resistance level?
However, on the 4-hour chart, APT’s price was rising but facing a huge blockade at $0.8777. Every time the price hit this level, it got rejected and even had a fake breakout five days ago.

At press time, APT was trading above $0.8777, with the same faintly flipping the SuperTrend indicator to bullish. Still, it wasn’t confirmation if the altcoin’s bulls can keep it out of this consolidation.

This may be why the RSI Divergence has been bearish. However, it broke above the neutral level with a reading of 62.41.

Source: APT/USDT on TradingView
Therefore, the sustained APT uptrend could face rejection at $0.9653, a level that triggered a sharp drop to $0.7620. If buyers keep charging, the altcoin may reclaim $1 now that a network upgrade is in place and is boosting activity.

Final Summary

APT rallied by over 13% after Aptos Labs announced a network upgrade to Block-STM v2. 
APT broke above the $0.8777 resistance level, with bulls now targeting $1. 

Enso, the Zurich-based execution infrastructure platform for onchain finance, has made xStocks available on Arbitrum through its API and RWA App. The integration means wallets, fintechs and trading platforms already connected to the Enso API can extend tokenized US equity access to Arbitrum without constructing new routing or aggregation infrastructure.
xStocks are tokenized representations of US-listed equities. By routing them through Enso’s existing execution layer, applications gain access alongside the same infrastructure already used for swaps, cross-chain routing and other DeFi actions across the networks Enso supports. Eligible users can also trade xStocks directly through the Enso RWA App within Arbitrum’s onchain ecosystem.

The distribution problem in tokenized assets
Connor Howe, co-founder and chief executive of Enso, identified what he sees as the core structural gap in real-world asset (RWA) markets. “Tokenization solved the supply side of real-world assets but what’s been missing is distribution, the liquidity, routing and execution to get those assets into the wallets and apps where people actually transact,” he said. “Bringing that to Arbitrum means any wallet, fintech or trading platform already built on Enso can offer tokenized equity access to one of Ethereum’s largest ecosystems without building anything new.”

The point is well-grounded in the current state of the market. Tokenized equity issuance has expanded materially over the past two years, but access has remained fragmented. Each new chain or venue has typically required application developers to build bespoke integrations, raising the cost and slowing adoption. Enso’s pitch is a single API that absorbs that complexity, a model it says is already powering ether.fi Cash’s tokenized stock and metals execution, an approved minting role for Ondo Finance, and the infrastructure behind Anchorage Digital’s Porto institutional terminal.

Peter Haymond, head of DeFi partnerships at Arbitrum, said real-world assets are one of the fastest-growing categories on the network and that execution infrastructure is what converts that growth into something developers can ship. The xStocks integration, he argued, is the kind of composability that compounds as more real-world assets move onchain.

Regulatory backdrop and market momentum
The timing sits against a broader wave of institutional interest in tokenized equities. The announcement noted that NYSE parent ICE and crypto exchange OKX filed with the US Securities and Exchange Commission this week for a 24/7 venue that would trade more than 60 tokenized US stocks. If approved, that would mark a significant step in legitimising tokenized equity infrastructure as a regulated asset class rather than a DeFi experiment.

In the EU, MiCA provides a framework for certain crypto-asset types, but tokenized securities remain subject to existing securities law, meaning any platform offering them to European users must navigate MiFID II compliance. In the UK, the Financial Conduct Authority‘s sandbox for digital securities is still developing clear rules. The regulatory path for tokenized equities therefore varies by jurisdiction, and Enso’s release does not specify which users are eligible to trade through the RWA App or which regulatory frameworks govern its institutional clients.

Enso says it has settled more than $22 billion onchain for more than 350 enterprise clients. The company is backed by Polychain Capital, Multicoin Capital, Spartan Group and Hypersphere, though no new funding was announced alongside this integration.

AI level 1 of 5: written by Darlyn Ho; AI helped with tone, structure or wording; edited and signed off by Mark Walker, Editorial Director. What the levels mean

Assenagon Asset Management S.A. grew its holdings in shares of MKS Inc. (NASDAQ:MKSI – Free Report) by 1,742.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 442,273 shares of the scientific and technical instruments company’s stock after buying an additional 418,264 shares during the period. Assenagon Asset Management S.A. owned 0.65% of MKS worth $117,362,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Loftus Peak Pty Ltd boosted its position in shares of MKS by 21.4% in the 3rd quarter. Loftus Peak Pty Ltd now owns 57,593 shares of the scientific and technical instruments company’s stock worth $15,283,000 after purchasing an additional 10,157 shares in the last quarter. First Citizens Bank & Trust Co. purchased a new stake in shares of MKS in the third quarter worth $575,000. NorthCrest Asset Manangement LLC increased its holdings in shares of MKS by 19.5% during the third quarter. NorthCrest Asset Manangement LLC now owns 1,262 shares of the scientific and technical instruments company’s stock valued at $329,000 after acquiring an additional 206 shares in the last quarter. Wedmont Private Capital increased its holdings in shares of MKS by 2.3% during the third quarter. Wedmont Private Capital now owns 4,193 shares of the scientific and technical instruments company’s stock valued at $1,092,000 after acquiring an additional 95 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of MKS by 13.5% during the third quarter. GAMMA Investing LLC now owns 3,667 shares of the scientific and technical instruments company’s stock valued at $973,000 after acquiring an additional 436 shares in the last quarter. 99.79% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades Several brokerages recently commented on MKSI. Deutsche Bank Aktiengesellschaft set a $360.00 price objective on shares of MKS in a research report on Friday, July 31st. Wall Street Zen raised shares of MKS from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Bank of America upped their target price on shares of MKS from $380.00 to $500.00 and gave the stock a “buy” rating in a research note on Tuesday, June 23rd. Needham & Company LLC increased their price target on shares of MKS from $360.00 to $390.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, Citigroup increased their price target on shares of MKS from $425.00 to $430.00 and gave the company a “buy” rating in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $375.93.

Get Our Latest Report on MKS MKS Trading Down 6.0% MKSI opened at $214.83 on Friday. The company has a current ratio of 1.14, a quick ratio of 0.72 and a debt-to-equity ratio of 0.85. MKS Inc. has a 12 month low of $130.72 and a 12 month high of $447.62. The firm has a market cap of $14.53 billion, a P/E ratio of 34.26, a P/E/G ratio of 0.48 and a beta of 2.03. The stock has a 50-day moving average of $265.44 and a 200 day moving average of $299.66.

MKS (NASDAQ:MKSI – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The scientific and technical instruments company reported $3.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.91 by $0.39. The company had revenue of $1.25 billion during the quarter, compared to analysts’ expectations of $1.20 billion. MKS had a return on equity of 24.72% and a net margin of 10.15%. MKS’s revenue was up 28.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.77 EPS. MKS has set its Q3 2026 guidance at 3.270-3.890 EPS. As a group, research analysts forecast that MKS Inc. will post 13.13 EPS for the current year.

MKS Announces Dividend The business also recently announced a quarterly dividend, which was paid on Thursday, September 3rd. Shareholders of record on Tuesday, August 25th were given a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Tuesday, August 25th. MKS’s dividend payout ratio (DPR) is 15.95%.

Insider Buying and Selling at MKS In related news, Director Elizabeth Mora sold 300 shares of the business’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $250.96, for a total transaction of $75,288.00. Following the transaction, the director directly owned 18,845 shares in the company, valued at $4,729,341.20. The trade was a 1.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Williams sold 457 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $288.31, for a total value of $131,757.67. Following the sale, the executive vice president owned 4,098 shares in the company, valued at $1,181,494.38. The trade was a 10.03% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 10,757 shares of company stock valued at $3,227,146. 0.57% of the stock is currently owned by insiders.

MKS Company Profile (Free Report)

MKS Instruments, Inc develops technologies used to measure, control and analyze the processes involved in manufacturing semiconductors, electronics, specialty materials and other industrial products. The company serves original equipment manufacturers and production facilities worldwide, with solutions spanning vacuum control, pressure measurement, gas and fluid delivery, process monitoring and control.

Its product portfolio includes vacuum gauges and valves, mass flow controllers, gas and vapor delivery systems, pressure controllers, plasma-generation and power-delivery systems, analytical instruments, lasers and photonics equipment.

Featured Articles Five stocks we like better than MKS Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out? Want to see what other hedge funds are holding MKSI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MKS Inc. (NASDAQ:MKSI – Free Report).

Receive News & Ratings for MKS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MKS and related companies with MarketBeat.com's FREE daily email newsletter.

Not all high-yield dividend stocks are created equal. Some are genuine income compounders, while others are traps. And the current environment, with interest rates on the rise, makes it more difficult to differentiate the good from the bad.

AbbVie (ABBV +0.71%) is by no means a high-yield trap. This pharma stock is well-positioned to succeed in any rate cycle.

Image source: Getty Images.

The exact opposite of a high-yield trap What makes a stock a high-yield trap? Different investors can have different criteria, but there's one tell-tale sign. A stock with a high dividend yield but a payout ratio consistently above its free cash flow is almost always a trap. If a company doesn't generate sufficient free cash flow, it will be forced to cut its dividend sooner or later.

Rising interest rates make it especially difficult for companies with balance sheets loaded to the gills with floating-rate debt. They frequently must shift funds from the dividend program to cover their higher interest expenses.

Similarly, a company with a business model whose revenue is highly sensitive to consumer spending can experience problems when rates increase. When consumers have to spend more of their money on car and home loans and credit card debt, they have less money to buy these companies' products.

AbbVie doesn't have issues on any of these fronts. The drugmaker generates more than enough free cash flow to cover its quarterly dividend payment of $1.73 per share. While AbbVie's debt totals $70.8 billion, much of it is in fixed-rate senior notes that aren't sensitive to interest rate fluctuations. Patients don't quit taking AbbVie's medications because interest rates go up, either.

ABBV AbbVie$285.42+$2.02 (+0.71%)

NYSE · As of 4:00 PM ET 10/16/26

The numbers add up for AbbVie Importantly, AbbVie has increased its dividend for 54 consecutive years (including the period when it was part of Abbott Laboratories (ABT +0.20%)). This achievement qualifies the company to be part of the Dividend Kings, a group of stocks that have increased their dividends for at least 50 consecutive years.

As you might imagine, Dividend Kings are loath to break their dividend-hike streaks and lose their status in the elite group. Both Abbott and AbbVie have ensured their dividends keep flowing and growing regardless of what the Federal Reserve does with rates.

AbbVie shouldn't have much trouble holding onto its Dividend King membership for two key reasons: Skyrizi and Rinvoq. These two autoimmune disease drugs together raked in over $7.5 billion in the second quarter of 2026 alone. That's more than the $6.1 billion the company paid in dividends during the quarter.

Another important number to know is 90. That's roughly how many programs the company has in clinical development. Around 60 of them are in mid- or late-stage clinical studies. This robust pipeline should help ensure that AbbVie continues to generate plenty of revenue in the future to grow its dividend.

A Dividend King to own for the long run To be sure, AbbVie's dividend yield of 2.5% isn't nearly as high as it's been in the past. However, that isn't a poor reflection on the company's ability to pay dividends. Instead, it's a testament to how great AbbVie's stock has performed in recent years. Its share price has risen so much that the solid dividend growth hasn't kept pace, causing this yield to slide.

Like all biotech and pharmaceutical companies, AbbVie faces the risk of pipeline setbacks. The good news, though, is that the company has enough therapies in development to remain successful even if some don't fulfill their potential.

In a market where investors can easily get stuck with high-yield traps, AbbVie offers a solution. It's an ideal Dividend King to own for the long run.

Shares of ad tech company The Trade Desk (TTD -6.86%) trade near $12 as I write, down about 91% from their December 2024 record closing price of $139.51. And shares have kept sliding this year, down about 68% since the end of 2025.

The company's now worth about $5.8 billion, and the stock costs about 14 times its earnings for the last 12 months. For a business whose revenue rose 18% year over year in 2025, that looks cheap. But management now expects revenue to shrink.

Where could the stock realistically be in a bit over three years?

My estimate is around $16 a share by the end of 2029, about 31% above today's price, or a gain of about 9% a year. I think it's a fair middle case. But it hinges on something the company hasn't forecast yet: a return to growth.

Image source: Getty Images.

Shrinking sales, fewer sharesThe Trade Desk is a tech company that runs a demand-side platform (software advertisers use to buy digital ads automatically), and as recently as last year the business looked healthy. Full-year 2025 revenue hit around $2.9 billion, and net income climbed about 13% to $443 million -- a net margin of about 15%.

Growth has since slowed sharply. Second-quarter 2026 revenue rose just 3% year over year to $715 million. Net income dropped around 29% to $64 million, cutting the net margin to 9% from 13% in the year-ago quarter. And management's guidance calls for third-quarter revenue of at least $650 million, which would be a decline of about 12% from the same period in 2025.

Still, one number keeps moving in shareholders' favor. Mainly because of buybacks, the company's diluted share count dropped from around 507 million in late 2024 to 483 million a year later, then to 470 million by this year's second quarter. The Trade Desk repurchased about 10 million shares for about $233 million in the first half of 2026 alone, and it still had about $1.5 billion in cash and short-term investments and no debt at the end of June.

So per-share earnings can arguably rise faster than profits, even if the business recovers slowly.

What would it take to hit $16?Say revenue rebounds to 2025's level of about $2.9 billion by 2027 and then rises about 6% a year. This gets The Trade Desk to about $3.3 billion of revenue in 2029, growth at about a third of the rate it managed in 2025.

If the net margin also returns to the 15% the business had in 2025, net income could be near $490 million in 2029.

Assume buybacks cut the diluted share count to about 450 million, a slower rate of decline than the past 18 months. That works out to about $1.09 of earnings per share.

At 15 times earnings (near the price-to-earnings ratio the stock trades at now), shares would be worth around $16.

Notably, I'm not assuming a higher valuation multiple, just that the company stops shrinking and earns its 2025 net margin again.

$12.23-$0.90 (-6.86%)

NASDAQ · As of 4:00 PM ET 10/16/26

A lot could go wrongThe biggest risk is that revenue doesn't rebound on that schedule. If sales settle around $2.8 billion and the net margin stalls at about 10%, earnings per share could be about $0.61 on 460 million shares. At 12 times earnings, the stock would be worth around $7, or about 40% below its current price.

The share count assumption has its own risk. On Monday, Oct. 19, shareholders vote on a proposal to reprice stock options for up to around 15.6 million shares, or about 3% of the outstanding shares. Exercise prices for these options go up to $122.59, and if the proposal passes, any above that day's closing price would be cut to the close. Options priced near the stock might increase dilution if shares recover, which is the scenario my forecast assumes.

In the end, a gain of around 9% a year would be a decent result from here. But it hinges on a recovery The Trade Desk hasn't guided to, and my bear case drops more than my base case climbs. This prediction doesn't change the take I spelled out last month, when I explained why I'm still not buying the stock.

Until management's revenue forecast points up again, I'd rather not pay even 14 times earnings for the shares. Sure, three years is a long time, and my estimate could miss in either direction.

The Euro-Dollar Edges Higher Near $1.124 as Nordea Cuts Its Recovery Outlook
Nordea analysts forecast the Euro to weaken against the US Dollar as French fiscal risks and US investment flows outweigh the currency's latest recovery.
The Euro-to-Dollar exchange rate edged higher on Friday, trading at $1.1237 ahead of the weekly close, although EURUSD remained about 2% lower over the past month.

Latest-Exchange Rates:

Euro to Dollar (EUR/USD): 1.12394 (+0.23%)

Pound to Dollar (GBP/USD): 1.33301 (+0.44%)

Dollar to Yen (USD/JPY): 157.99261 (-0.09%)

FX analysts at Nordea expect that recovery to falter, having cut its end-2026 EUR/USD forecast to 1.10 from 1.14 after the exchange rate reached its previous first-half 2027 objective sooner than anticipated.

The bank now sees a test of 1.08 in the first half of next year.

Nordea argues that France's financing difficulties and continued demand for American technology investments leave Europe at a disadvantage even after the Euro's recent losses.

That is a more cautious December view than the latest projections from UBS and Crédit Agricole, which put EUR/USD at 1.16 and 1.13 respectively for end-2026.

France's higher yields carry a different message
Higher bond yields can attract currency demand when they reflect stronger growth and better prospective returns.

Nordea sees a less reassuring explanation for the extra yield investors require to hold French government bonds rather than German Bunds.

The bank writes: "The sharp widening in OAT-Bund spreads therefore appears to reflect more than a routine bout of risk aversion around the French budget. Markets are assigning a broader premium to France's fiscal and political outlook, reinforcing downside risks to the euro."

France's challenge is to convince investors that its borrowing needs can be contained while it negotiates a credible 2027 budget ahead of next year's presidential election.

With debt-servicing costs increasing, further monetary tightening could make that task harder even if it helps restrain inflation.

Nordea identifies a problem extending beyond France: "The pressure is greatest in highly indebted economies, where weak growth and limited appetite for reform leave public finances increasingly exposed to higher global yields."

It adds: "Unlike the US, these economies lack the nominal growth needed to offset rising borrowing costs, further constraining fiscal space as interest expenses climb."

Exchange Rates UK's coverage of France's increasingly country-specific borrowing premium also examined why a rise in French yields need not strengthen the Euro.

Money switching into other Euro-denominated assets would have a different currency effect from investors reducing their exposure to the region altogether.

Inflation does not give Europe the same rate advantage
Friday's final Eurostat inflation release confirmed annual price growth of 3.8% in September, with energy making the largest contribution.

That keeps pressure on the European Central Bank, but Nordea expects expensive energy to favour the US relative to Europe through its effect on trade and economic activity.

A larger import bill can squeeze European household and business spending while supporting income in an energy-producing economy.

Nordea's policy assessment is explicit: "Our baseline remains a strong US economy and two further Fed hikes, with risks skewed to the upside. By contrast, the balance of risks around the ECB's hawkish stance has shifted to the downside, keeping the short-end rate differential in the dollar's favor."

The difference in expected short-term rates influences the relative return available on Dollar and Euro assets.

Subsequent US activity figures give that argument some support without settling the policy outlook.

The Federal Reserve's September industrial-production report, released on Friday, showed output rising 0.7% on the month, although a large utilities increase helped drive the headline gain.

Manufacturing rose a more modest 0.3%, so the report offers evidence of continued expansion rather than an equally strong acceleration across industry.

The Dollar call depends on investment holding up
A rate advantage is only part of Nordea's explanation for persistent Dollar demand.

"Inflows into US equities and credit are unlikely to fade simply because interest rates are slightly higher."

"Passive investment reinforces this trend because broad indices remain heavily concentrated in US mega-cap technology stocks. To the extent that these flows remain unhedged, they create sustained demand for dollars."

Overseas investors can protect themselves against exchange-rate movements, reducing the net currency exposure associated with buying American assets.

The possible stabilisation discussed in our earlier coverage of Scotiabank's oversold-Euro assessment concerns a shorter horizon than Nordea's fundamental call.

A rebound need not require an immediate reversal in the investment flows supporting the Dollar.

For now, Nordea finds little evidence that the cycle is turning: "South Korean and Taiwanese exports are improving, as are global PMIs, while earnings have remained solid and repeatedly exceeded analysts' expectations in recent quarters. These indicators do not rule out high valuations, but they provide little evidence that the investment cycle is already turning."

Nordea does expect conditions to become more favourable for the Euro later in 2027 as US inflation eases and Fed tightening ends.

An earlier disruption to technology investment could bring that reassessment forward: "The main risk to our EUR/USD forecast is a sharp reversal in the AI investment cycle. A bursting AI "bubble" would weaken US asset inflows and challenge our dollar-positive view."

Euro to Dollar exchange rate FAQ
What is Nordea's EUR/USD forecast?

Nordea has cut its end-2026 projection to 1.10 and expects a test of 1.08 in the first half of 2027.

Why does Nordea expect further Euro weakness?

It points to US rate support, European fiscal and energy pressures, and continued investment flows into American assets.

What could challenge that forecast?

An abrupt reversal in AI investment could weaken US capital inflows and undermine Nordea's positive Dollar view.

Walt Disney's (DIS -0.08%) place is in the living room. Its popular cable channels helped it establish a dominant position in the media and entertainment industry. But this part of the business faces secular decline, as U.S. households have been cutting the cord. The linear networks aren't as lucrative as they once were.

The company has transitioned successfully this decade in the streaming age. It's been a costly evolution, though. But Disney+, Hulu, and the direct-to-consumer (DTC) ESPN platform give Disney a comprehensive content offering that caters to everyone in the family.

While changes have happened on the TV screen, the experiences segment continues to drive the lion's share of financial results. And the business is investing aggressively here.

Shareholders have witnessed multiple CEO changes, from Bob Chapek to Bob Iger to Josh D'Amaro. And the consumer discretionary stock has disappointed amid all of this turbulence. It currently trades 46% off its peak (as of Oct. 14). And it's down 4% in 2026, lagging the broader market.

There's one stat, however, that makes the House of Mouse hard to ignore in October.

Image source: The Motley Fool.

The valuation represents a discount to the market Disney shares trade at a forward price-to-earnings ratio of 13.8 right now. That's significantly cheaper than the S&P 500's 19.6 multiple. It looks like a compelling bargain opportunity. That point carries extra weight when the market is near record territory. And given that it's been four years since this raging bull market started, investors might find it challenging to identify reasonably valued stocks.

As noted earlier, Disney hasn't been running a simple and easy-to-follow business. It seems that there are a lot of moving parts. And the market could be punishing the stock because of it.

The legacy cable networks continue to be a financial drag. From fiscal 2022 to fiscal 2025 (last available data), operating income fell 65%. That's not surprising because, according to eMarketer, the number of cable-TV households in the U.S. will decline again in 2026 to 54 million. That's down from 105 million households in 2010. Consumers have increasingly moved their attention to streaming entertainment, which has hurt legacy media players.

And this is a capital-intensive business. In addition to expanding its experiences division, Disney must constantly invest in content that seems to get more expensive every year. This is particularly true with valuable sports rights. Big tech enterprises have entered the arena, which can result in costly bidding wars.

Competition for eyeballs is also intense these days. And it's a crowded race to capture consumer discretionary spending. Moreover, the investment community might simply be chasing what has been the hottest trade, which is owning artificial intelligence stocks.

$110.59-$0.09 (-0.08%)

NYSE · As of 4:00 PM ET 10/16/26

Take a five-year view Knowing the negative factors, I still believe the valuation makes Disney shares too hard to ignore this month. For less than 14 times forward earnings, investors can own a stake in a high-quality company.

It all starts with something that no rival can copy, which is Disney's intellectual property (IP). Decades of characters, franchises, and stories can't be rebuilt with any amount of capital. This supports the company's economic moat.

The entertainment DTC operations, including Disney+ and Hulu (excluding live TV), have turned the corner on profitability. Operating income soared more than 100% year over year in Q3 (ended June 27) to $712 million. In fiscal 2022, it posted a sizable operating loss of $4 billion (including ESPN+). This is an emerging bottom-line tailwind.

Then there's the experience segment. The main drivers here are the theme parks and cruises, both of which are expanding as part of a 10-year, $60 billion capital expenditure cycle announced three years ago. The segment's Q3 operating income of $3 billion, accounting for 54% of the company's total, demonstrates how lucrative it is for Disney to bring its IP to life.

Patient investors with a five-year horizon have plenty to like here.

20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs
Latest long-term and real-world data with SKYRIZI®(risankizumab) and RINVOQ® (upadacitinib) provide additional insight into clinical and endoscopic outcomes over approximately three years in moderately to severely active Crohn's disease and ulcerative colitis
New data evaluating endoscopic remission with investigational dual-targeting therapy ABBV-466 in patients with moderate-to-severe Crohn's disease will also be presented

, /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of 20 new scientific abstracts from its IBD portfolio at the 2026 United European Gastroenterology (UEG) Week, October 17-20 in Barcelona, Spain. Together, the data reflect the breadth of AbbVie's research across IBD, including established therapies studied over longer treatment periods and in real-world clinical practice.

"Crohn's disease and ulcerative colitis are chronic, lifelong conditions, and understanding how patients respond to treatment over time and in everyday clinical practice is critical," said Sofie Berg, Pharm.D., Ph.D., therapeutic area head, immunology, international medical affairs, AbbVie. "The data presented at UEGW 2026 build on our growing body of evidence that can help clinicians move toward favorable long-term outcomes for people living with IBD."

Key data to be presented include:

Long-term data in moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) – Open-label extension and post-hoc analyses add to the evidence base for clinical and endoscopic outcomes with risankizumab and upadacitinib

Risankizumab in UC: COMMAND showed sustained clinical and endoscopic outcomes up to three years of maintenance treatment. As-observed clinical remissiona rates of 54.0%–73.1% and endoscopic remissionb rates of 38.8%–53.5% were achieved at week 96 with 180mg across advanced therapy-naïve and advanced therapy-experienced patients.
Upadacitinib in CD: U-ENDURE as-observed analyses showed that clinical and endoscopic outcomes were maintained through approximately four years of treatment. At Week 144, clinical remissionc was achieved by 78.9% of patients receiving 15 mg and 86.6% receiving 30 mg. Endoscopic remissiond was achieved by 47.1% and 64.2% of patients, respectively.

Upadacitinib in the Real World: New Insights from Clinical Practice

Interim results from the real-world UPlift study showed that 70.2% of evaluable patients (N=497) with moderate to severe Crohn's disease achieved clinical responsee with upadacitinib within 12 weeks, with a median time to first response of 13 days.
A real-world claims analysis of patients (N=514) with UC or CD showed that patients who switched from a Tumor Necrosis Factor inhibitor (TNFi) to upadacitinib had lower rates of IBD-related hospitalizations (9.5% vs 16.3%) or surgery (6.9% vs 10.6%) over 12 months compared with patients who cycled to another TNFi.

Additional Findings on Risankizumab Subcutaneous Induction in CD

Data presented at UEGW will further expand on findings from the Phase 3 AFFIRM study evaluating subcutaneous risankizumab induction and maintenance in CD. Following the first presentation of AFFIRM results at the 2026 American College of Gastroenterology Annual Scientific Meeting, the UEGW presentations will provide additional analyses examining outcomes by prior advanced therapy exposure and further characterizing clinical and endoscopic outcomes among patients who responded to subcutaneous risankizumab induction and continued treatment.

aDefined as stool frequency (SF) score ≤ 1, and not greater than baseline, rectal bleeding score = 0, and endoscopic subscore ≤ 1 without evidence of friability.
bDefined as endoscopic subscore = 0.
cDefined as average daily very soft or liquid SF ≤2.8 and average daily abdominal pain (AP) score ≤1.0 and both not greater than induction baseline.
dDefined as Simplified Endoscopic Score for Patients with Crohn's Disease ≤ 4 and at least a 2-point reduction from baseline and no subscore > 1 in any individual variable, as scored by a central reviewer.
eDefined as the first day with ≥30% decrease in daily very soft or liquid SF and/or ≥30% decrease in daily AP score and both not worse than baseline AND a prospective 7-day average daily CR-PRO starting on the first day of daily CR-PRO; prospective 7-day average daily CR-PRO was defined as ≥30% decrease in average daily very soft or liquid SF and/or ≥30% decrease in average daily AP score and both not worse than baseline. Only patients with either baseline SF or AP >0 and both non-missing with at least one postbaseline assessment of CR-PRO2 are included.

The 2026 UEGW Congress program is available here. Select abstracts and oral presentations from AbbVie include:

Presentation Title

Session Details

Efficacy of Risankizumab by Crohn's Disease
Location: Results From 144 Weeks of the
FORTIFY Open-Label Extension Study

Oral

Monday, 19 October

16:00 – 17:00

OP165: Teaching an old dog new tricks:
New implementations of current IBD drug

Efficacy and Safety of Risankizumab
Subcutaneous Induction in Patients With
Moderately to Severely Active Crohn's Disease:
Week 12 Results From the Phase 3 AFFIRM Study

Oral

Monday, 19 October

16:00 – 17:00

OP166: Teaching an old dog new tricks:
New implementations of current IBD drug

Efficacy and Safety of Subcutaneous
Risankizumab Maintenance Therapy Among
Patients With Moderately to Severely Active
Crohn's Disease Who Responded to
Subcutaneous Risankizumab Induction Therapy:
24-Week Results From the AFFIRM Trial

Moderated poster

Monday, 19 October

16:00 – 17:00

MP0087: The IBD exposome: Diet,
environment, and sustainability

Sustained Clinical and Endoscopic Improvements With
up to 3 Years of Risankizumab Maintenance
Treatment in Patients with Moderate to Severe
Ulcerative Colitis Regardless of the Number of Prior
Advanced Therapy Exposures

E-Poster

17-20 October

PP1176

Efficacy and Safety of Upadacitinib Maintenance
Therapy in Moderately to Severely Active
Crohn's Disease: 144-Week Results From the U-
ENDURE Long-Term Extension Study

Oral

Monday, 19 October

11:30 – 12:30

OP108: Long term outcomes
of interventional trials in IBD

Effectiveness of Upadacitinib Treatment in
Moderate to Severe Crohn's Disease in Real-
World Clinical Practice: 6-Month Results From
the UPlift Study

Moderated poster

Sunday, 18 October

09:00 – 10:00

MP0015: Therapeutics in IBD - Real
world experience (3)

Comparative Health Care Resource Use and
Treatment Patterns Following Tumor Necrosis
Factor Inhibitor Cycling Versus Switching to
Upadacitinib: A Propensity Score Matched
Analysis

Oral

Tuesday, 20 October

14:30 – 15:30

OP292: Real world observations in IBD:
Things we don't see in clinical trials

ABBV-466, A Novel Dual-targeting Therapy,
Leads to Endoscopic Remission in Moderate-to-
severe Crohn's Disease: Primary Results and

Molecular Profiling from the Phase 2a TARGET-
CD study

Oral

Monday, 19 October

10:00 – 11:00

LB08: Late-Breaking IBD Trials 

SKYRIZI® (risankizumab) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally. 

About SKYRIZI®
SKYRIZI is an interleukin (IL)-23 inhibitor that selectively blocks IL-23 by binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.1 SKYRIZI is approved by the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of moderately to severely active plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.1,2

On August 27, 2026, AbbVie announced submission of an application to the European Medicines Agency (EMA) seeking approval of SKYRIZI® for subcutaneous induction for the treatment of adult patients with moderately to severely active CD.

EU Indications and Important Safety Information about SKYRIZI® (risankizumab)1 

Indications

Skyrizi (risankizumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

Skyrizi is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.

Skyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).

Skyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Skyrizi is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Important Safety Information

Risankizumab is contraindicated in patients hypersensitive to the active substance or to any of the excipients, and in patients with clinically important active infections (e.g. active tuberculosis).

Risankizumab may increase the risk of infection. In patients with a chronic infection, a history of recurrent infection, or known risk factors for infection, risankizumab should be used with caution. Treatment with risankizumab should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.

Patients treated with risankizumab should be instructed to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops such an infection or is not responding to standard therapy for the infection, the patient should be closely monitored and risankizumab should not be administered until the infection resolves.

Prior to initiating treatment with risankizumab, patients should be evaluated for tuberculosis (TB) infection. Patients receiving risankizumab should be monitored for signs and symptoms of active TB. Anti-TB therapy should be considered prior to initiating risankizumab in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.

Prior to initiating therapy with risankizumab, completion of all appropriate immunizations should be considered according to current immunization guidelines. If a patient has received live vaccination (viral or bacterial), it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab. Patients treated with risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment.

Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of risankizumab. If a serious hypersensitivity reaction occurs, administration of risankizumab should be discontinued immediately and appropriate therapy initiated.

The most frequently reported adverse reactions were upper respiratory infections (13% in psoriasis, 15.6% in Crohn's disease and 26.2% in ulcerative colitis).

Commonly (≥ 1/100 to < 1/10) reported adverse reactions included tinea infections, headache, pruritus, rash, eczema, fatigue, and injection site reactions.

This is not a complete summary of all safety information.

See Skyrizi full Summary of Product Characteristics (SmPC) at http://www.ema.europa.eu 

Globally, prescribing information varies; refer to the individual country product label for complete information.

About RINVOQ® (upadacitinib)
Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.3,4 In human cellular assays, RINVOQ preferentially inhibits signaling by JAK1 or JAK1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2.3

Upadacitinib (RINVOQ) is being studied in Phase 3 clinical trials for hidradenitis suppurativa, Takayasu arteritis and systemic lupus erythematosus and in pediatric studies for systemic juvenile idiopathic arthritis, atopic dermatitis, ulcerative colitis and Crohn's disease.

EU Indications and Important Safety Information about RINVOQ® (upadacitinib)3

Indications

Rheumatoid arthritis
RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.

Psoriatic arthritis
RINVOQ is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

Polyarticular juvenile idiopathic arthritis
RINVOQ is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) [polyarticular rheumatoid factor positive {RF+} or negative {RF-}, extended oligoarticular], in patients 2 years of age and older who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.

Axial spondyloarthritis
Non-radiographic axial spondyloarthritis (nr-axSpA) 
RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)
RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.

Giant cell arteritis
RINVOQ is indicated for the treatment of giant cell arteritis (GCA) in adult patients.

Atopic dermatitis
RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents 12 years and older who are candidates for systemic therapy.

Alopecia areata
RINVOQ is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older.

Vitiligo
RINVOQ is indicated for the treatment of non-segmental vitiligo in adults and adolescents 12 years and older who are candidates for systemic therapy.

Ulcerative colitis
RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Crohn's disease
RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Important Safety Information

Contraindications
RINVOQ is contraindicated in patients hypersensitive to the active substance or to any of the excipients, in patients with active tuberculosis (TB) or active serious infections, in patients with severe hepatic impairment, and during pregnancy.

Special warnings and precautions for use
RINVOQ should only be used if no suitable treatment alternatives are available in patients:

- 65 years of age and older;
- patients with history of atherosclerotic cardiovascular (CV) disease or other CV risk factors (such as current or past long-time smokers);
- patients with malignancy risk factors (e.g. current malignancy or history of malignancy).

Use in patients 65 years of age and older
Considering the increased risk of MACE, malignancies, serious infections, and all-cause mortality in patients ≥65 years of age, as observed in a large randomised study of tofacitinib (another Janus Kinase (JAK) inhibitor), RINVOQ should only be used in these patients if no suitable treatment alternatives are available. In patients ≥65 years of age, there is an increased risk of adverse reactions with RINVOQ 30 mg once daily. Consequently, the recommended dose for long-term use in this patient population is 15 mg once daily.

Immunosuppressive medicinal products
Use in combination with other potent immunosuppressants is not recommended.

Serious infections
Serious and sometimes fatal infections have been reported in patients receiving RINVOQ. The most frequent serious infections reported included pneumonia and cellulitis. Cases of bacterial meningitis and sepsis have been reported with RINVOQ. Among opportunistic infections, TB, multidermatomal herpes zoster, oral/esophageal candidiasis, and cryptococcosis have been reported. RINVOQ should not be initiated in patients with an active, serious infection, including localized infections. RINVOQ should be interrupted if a patient develops a serious or opportunistic infection until the infection is controlled. A higher rate of serious infections was observed with RINVOQ 30 mg compared to 15 mg. As there is a higher incidence of infections in the elderly and patients with diabetes in general, caution should be used when treating these populations. In patients ≥65 years of age, RINVOQ should only be used if no suitable treatment alternatives are available.

Tuberculosis
Patients should be screened for TB before starting RINVOQ. RINVOQ should not be given to patients with active TB. Anti-TB therapy may be appropriate for select patients in consultation with a physician with expertise in the treatment of TB. Patients should be monitored for the development of signs and symptoms of TB.

Viral reactivation
Viral reactivation, including cases of herpes zoster, was reported in clinical studies. The risk of herpes zoster appears to be higher in Japanese patients treated with RINVOQ. Consider interruption of RINVOQ if the patient develops herpes zoster until the episode resolves. Screening for viral hepatitis and monitoring for reactivation should occur before and during therapy. If hepatitis B virus DNA is detected, a liver specialist should be consulted.

Vaccination
The use of live, attenuated vaccines during or immediately prior to therapy is not recommended. It is recommended that patients be brought up to date with all immunizations, including prophylactic zoster vaccinations, prior to initiating RINVOQ, in agreement with current immunization guidelines.

Malignancy
Lymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including RINVOQ. In a large randomised active‑controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC), was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors. A higher rate of malignancies, including NMSC, was observed with RINVOQ 30 mg compared to 15 mg. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. In patients ≥65 years of age, patients who are current or past long-time smokers, or patients with other malignancy risk factors (e.g., current malignancy or history of malignancy), RINVOQ should only be used if no suitable treatment alternatives are available.

Hematological abnormalities
Treatment should not be initiated, or should be temporarily interrupted, in patients with hematological abnormalities observed during routine patient management.

Gastrointestinal perforations
Events of diverticulitis and gastrointestinal perforations have been reported in clinical trials and from post marketing sources. RINVOQ should be used with caution in patients who may be at risk for gastrointestinal perforation (e.g., patients with diverticular disease, a history of diverticulitis, or who are taking non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or opioids). Patients with active Crohn's disease are at increased risk for developing intestinal perforation. Patients presenting with new onset abdominal signs and symptoms should be evaluated promptly for early identification of diverticulitis or gastrointestinal perforation.

Major adverse cardiovascular events
MACE were observed in clinical studies of RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of MACE, defined as CV death, non-fatal myocardial infarction and non-fatal stroke, was observed with tofacitinib compared to TNF inhibitors. Therefore, in patients ≥65 years of age, patients who are current or past long-time smokers, and patients with history of atherosclerotic CV disease or other CV risk factors, RINVOQ should only be used if no suitable treatment alternatives are available.

Lipids
RINVOQ treatment was associated with dose-dependent increases in lipid parameters, including total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol.

Hepatic transaminase elevations
Treatment with RINVOQ was associated with an increased incidence of liver enzyme elevation. Hepatic transaminases must be evaluated at baseline and thereafter according to routine patient management. If alanine transaminase (ALT) or aspartate transaminase (AST) increases are observed and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis is excluded.

Venous thromboembolism
Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) were observed in clinical trials for RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a dose‑dependent higher rate of VTE including DVT and PE was observed with tofacitinib compared to TNF inhibitors. In patients with CV or malignancy risk factors, RINVOQ should only be used if no suitable treatment alternatives are available. In patients with known VTE risk factors other than CV or malignancy risk factors (e.g. previous VTE, patients undergoing major surgery, immobilisation, use of combined hormonal contraceptives or hormone replacement therapy, and inherited coagulation disorder), RINVOQ should be used with caution. Patients should be re-evaluated periodically to assess for changes in VTE risk. Promptly evaluate patients with signs and symptoms of VTE and discontinue RINVOQ in patients with suspected VTE.

Retinal vein occlusion
Retinal vein occlusion has been reported in patients treated with JAK inhibitors, including upadacitinib. Patients should be advised to promptly seek medical care in case they experience symptoms suggestive of retinal vein occlusion.

Hypersensitivity reactions
Serious hypersensitivity reactions such as anaphylaxis and angioedema have been reported in patients receiving RINVOQ. If a clinically significant hypersensitivity reaction occurs, discontinue RINVOQ and institute appropriate therapy.

Hypoglycemia in patients treated for diabetes
There have been reports of hypoglycemia following initiation of JAK inhibitors, including RINVOQ, in patients receiving medication for diabetes. Dose adjustment of anti-diabetic medication may be necessary in the event that hypoglycemia occurs.

Medication residue in stool
Reports of medication residue in stool or ostomy output have occurred in patients taking RINVOQ tablets. Most reports described anatomic (e.g., ileostomy, colostomy, intestinal resection) or functional gastrointestinal conditions with shortened gastrointestinal transit times. Patients should be instructed to contact their healthcare professional if medication residue is observed repeatedly. Patients should be clinically monitored, and alternative treatment should be considered if there is an inadequate therapeutic response.

Giant cell arteritis
RINVOQ monotherapy should not be used for the treatment of acute relapses as efficacy in this setting has not been established. Corticosteroids should be given according to medical judgement and practice guidelines.

Excipients with known effect
RINVOQ 1 mg/ml oral solution contains 0.3 mg sodium benzoate in each ml.

Adverse reactions
The most commonly reported adverse reactions in RA, PsA, and axSpA clinical trials (≥2% of patients in at least one of the indications) with RINVOQ 15 mg were upper respiratory tract infections, blood creatine phosphokinase (CPK) increased, ALT increased, bronchitis, nausea, neutropenia, cough, AST increased, and hypercholesterolemia. Overall, the safety profile observed in patients with psoriatic arthritis or active axial spondyloarthritis treated with RINVOQ 15 mg was consistent with the safety profile observed in patients with RA.

The most commonly reported adverse reactions in AD trials (≥2% of patients) with RINVOQ 15 mg or 30 mg were upper respiratory tract infection, acne, herpes simplex, headache, blood CPK increased, cough, folliculitis, abdominal pain, nausea, neutropenia, pyrexia, and influenza. Dose dependent increased risks of infection and herpes zoster were observed with RINVOQ. The safety profile for RINVOQ 15 mg and 30 mg in adolescents was similar to that in adults. With long-term exposure, skin papilloma was reported in adolescents in the RINVOQ 15 mg and 30 mg groups.

The most commonly reported adverse reactions in the UC and CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were upper respiratory tract infection, pyrexia, blood CPK increased, anemia, headache, acne, herpes zoster, neutropenia, rash, pneumonia, hypercholesterolemia, bronchitis, AST increased, fatigue, folliculitis, ALT increased, herpes simplex, and influenza. The overall safety profile observed in patients with UC was generally consistent with that observed in patients with RA. Overall, the safety profile observed in patients with CD treated with RINVOQ was consistent with the known safety profile for RINVOQ.

Overall, the safety profile observed in patients with GCA treated with RINVOQ 15 mg was generally consistent with the known safety profile for RINVOQ.

Overall, the safety profile observed in paediatric patients with pJIA treated with RINVOQ was consistent with the known safety profile of RINVOQ.

The safety profile of RINVOQ 15 mg and 30 mg observed in patients with alopecia areata was generally consistent with the known safety profile in patients with atopic dermatitis.

The safety profile of RINVOQ 15 mg observed in patients with vitiligo was generally consistent with the known safety profile in patients with atopic dermatitis. A higher incidence of hypercholesterolemia was observed in patients with vitiligo treated with RINVOQ 15 mg compared to placebo.

The most common serious adverse reactions were serious infections.

The safety profile of RINVOQ with long term treatment was generally similar to the safety profile during the placebo-controlled period across indications.

RINVOQ is available in 15 mg, 30 mg, and 45 mg prolonged-release tablets and 1 mg/ml oral solution. RINVOQ tablets and RINVOQ oral solution are not bioequivalent. Refer to the Summary of Product Characteristics for posology and method of administration.

This is not a complete summary of all safety information.

See RINVOQ full Summary of Product Characteristics (SmPC) at http://www.ema.europa.eu 

Globally, prescribing information varies; refer to the individual country product label for complete information.

About TARGET-CD:
TARGET-CD (M24-885) is a global Phase 2a, multicenter, randomized platform study designed to evaluate multiple investigational targeted therapies, including monotherapy and combination approaches, in adults with moderately to severely active Crohn's disease. The innovative platform design enables evaluation of the efficacy, safety, and mechanistic profiles of different therapeutic strategies using a common comparator, with the goal of rapidly advancing new treatment approaches for patients with Crohn's disease. More information on the TARGET-CD trial can be found at www.clinicaltrials.gov (NCT06548542).

About ABBV-466:
ABBV-466 is an investigational dual-targeting therapy combining risankizumab, an IL-23 inhibitor, with trosunilimab, an α4β7 inhibitor, to address complementary drivers of inflammation in Crohn's disease. The approach is designed to inhibit inflammatory signaling while limiting immune-cell trafficking to the gut, with the goal of achieving deeper disease control than either pathway alone.

ABBV-466 is investigational and its safety and efficacy have not been established by regulatory authorities.

About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For nearly 30 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.

Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References

SKYRIZI. Summary of product characteristics. AbbVie; 2026.
SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
RINVOQ. Summary of product characteristics. AbbVie; 2026.
Pipeline. AbbVie. 2026. Accessed September 24, 2026. https://www.abbvie.com/our-science/pipeline.html

SOURCE AbbVie

3 hours ago

Fidelity Digital Assets recently released an analysis noting that the 10-year U.S. Treasury yield has risen to its highest level since Bitcoin’s inception, while the size of U.S. federal debt has surpassed $40 trillion, with interest payments exceeding Medicare to become the second-largest expenditure item in the federal budget. Fidelity pointed out that Bitcoin’s correlation with the 10-year U.S. real interest rate was long low, but has gradually turned positive in recent years, rising above 0.6 in 2026, a record high. Over the past two months, Bitcoin has rallied nearly 30%, while the 10-year U.S. Treasury yield has jumped more than 10% in the same period. Fidelity argues that amid rising government debt, higher financing costs and growing concerns over fiscal intervention, Bitcoin’s fixed supply cap of 21 million coins may boost its appeal as a potential hedge against currency devaluation and a portfolio diversification tool. If current debt and interest rate trends persist, government interest payments could even become the largest expenditure item in the federal budget in the future. U.S. Treasury data shows that the U.S. federal budget deficit for fiscal 2026 rose to $1.99 trillion, up from $1.78 trillion in fiscal 2025, the highest level since the COVID-19 pandemic. Despite the Trump administration’s pledge to cut spending, military spending, Social Security expenditures and Treasury interest payments continue to climb, coupled with a decline in corporate tax revenue, further expanding the fiscal deficit.

Scan the QR code

Download APP

Ripple CEO Brad Garlinghouse has explained why the company contributed a significant amount of XRP to Evernorth, the XRP treasury company that recently debuted on Nasdaq. Speaking at Nasdaq on the company’s listing day, he said the move fits Ripple’s long-standing approach of investing in its own ecosystem, and that his trust in Evernorth’s leadership sealed the decision.

Why Ripple backed Evernorth

Asked why Ripple put its tokens into Evernorth, Garlinghouse said supporting the community has been part of Ripple’s strategy “since really its inception.” That support has sometimes reached beyond XRP, he added, because Ripple believes in “a multi-chain world.”

The deciding factor was Evernorth CEO Asheesh Birla, who previously worked under Garlinghouse at Ripple and later sat on its board. “When Asheesh raised his hand and expressed interest, that to me cemented our interests,” Garlinghouse said.

He described Birla as “an extraordinary leader” who has shown “unique acumen around talent, around strategy,” both at Ripple and now at Evernorth.

How it helps XRP

Garlinghouse said Evernorth’s listing strengthens the XRP ecosystem in three ways:

Liquidity and trust: The listing “furthers liquidity” and “trust in the XRP ecosystem,” he said.New investors: A listed company opens XRP to people who cannot easily access crypto markets directly. “Just that is a major step,” he said.More than buy-and-hold: Evernorth plans to use on-chain and off-chain strategies to earn yield and build institutional products, which he said “positions XRP to perform really well.”He also explained how hard it has been to reach this point. “There were a couple hundred various DATs trying to get public,” he said, referring to digital asset treasury companies. “The fact that we are here today with XRP trading is a big deal.”

“Ripple was on to something”

Garlinghouse reflected on Ripple’s years as an outsider in crypto. Many early crypto users held a strongly anti-establishment view, and Ripple drew criticism for building for banks and traditional finance.

“For a bunch of years, Ripple was a controversial contrarian because we were leaning into TradFi as our core customer set,” he said. Now the market has come around, and “a lot of other players in the industry recognise that hey, maybe Ripple was on to something there.”

The hard years are not over

Garlinghouse stopped short of declaring victory. “I’m not ready to say the hard years are behind us,” he said.

Still, he believes markets are underestimating the shift in the US. The United States accounts for about 22% of global GDP and spent years “leaning out” on crypto, he said. Now its institutions are “leaning in like they never have before.”

Story Ends Here

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Read the Next News

Cardano’s (ADA) price has come under pressure, declining 2.3% in the last 24 hours to $0.2248, despite a substantial rise in the network’s stablecoin market capitalization. Data from Cardanians (CRDN) shows that Cardano’s stablecoin market cap has expanded by 25.8% over the past 90 days, climbing to $68.3 million.

Stablecoin growth and top contributorsThis jump in stablecoin capitalization highlights growing activity in Cardano’s ecosystem, as dollar-pegged assets play a larger role in decentralized finance (DeFi) trading and application usage. According to Cardanians, USDC currently leads with $44.4 million, followed by USDM at $13.5 million and RealFi’s USDrf at $5.1 million.

Stablecoin market cap on Cardano $ADA has grown by 25.8% in the past 90 days. Currently it’s at $68.3M, led by USDC with $44.4M. RealFi’s USDrf launched just recently and has already reached $5.1M. Great to see the growth, hoping to see $100M+ soon!

The increase in stablecoin balances signals that users are increasingly utilizing Cardano for transactions, DeFi applications, and transfers, without frequently moving assets into traditional currencies.

Mini dictionary: Cardanians is a Cardano-focused analytics and advocacy community that tracks on-chain data, network metrics, and ecosystem trends. They share insights on ADA’s performance and growth, often through social media channels such as X.

ADA price under pressure, key technical levels in focusDespite the stablecoin uptrend, ADA’s price remains subdued. Technical charts from TradingView reveal that ADA fell back after touching $0.28 in early October, sliding below resistance at $0.2432. Traders now focus on the crucial support level near $0.2053, which could determine whether the token stabilizes or faces further downside.

A move above $0.2432 would see ADA return to its recent trading range, though bulls must sustain buying pressure to advance a recovery. Until then, ADA continues to trade below resistance, keeping sentiment uncertain.

StablecoinMarket Cap ($ million)USDC44.4USDM13.5USDrf5.1Total68.3If ADA maintains support above $0.2053, it could allow time for consolidation. A breakdown below this zone, however, would increase risk of further declines.

Technical indicators and market signalsCardano’s Relative Strength Index (RSI) is currently at 42.82, below its moving average of 53.70, suggesting weakening bullish momentum. The RSI remains above the oversold threshold of 30, meaning the market yet waits for a clear oversold signal.

The On-Balance Volume (OBV) indicator has dropped to approximately 45.25 billion, consistent with declining buying interest. Although both indicators suggest softer demand, traders look for signals such as the RSI rising above 50 or an uptick in OBV before confirming a turnaround.

Open interest and DeFi metricsCoinGlass data reveals that ADA futures open interest has decreased from around $650 million in early October to about $500 million now. Liquidations have been observed on both long and short positions during recent volatility, indicating that leveraged traders face pressure in both directions.

Decreasing open interest may reflect reduced speculative positions, but does not in itself confirm whether investors are favoring bullish or bearish bets. Monitoring stabilization in open interest, along with price momentum and support levels, could provide clearer insight for traders.

Separately, DeFiLlama shows Cardano’s total value locked (TVL) has reached $65.21 million, while decentralized exchange (DEX) volume stands at $1.45 million for the past day. These figures highlight ongoing activity in Cardano’s DeFi ecosystem as stablecoin balances grow.

While higher stablecoin capitalization indicates expansion, it does not guarantee an increase in DeFi participation or demand for ADA itself. Traders continue to watch for a link between rising on-chain volumes, ecosystem usage, and a shift in price momentum.

In the near term, ADA’s outlook hinges on whether positive network indicators join with technical recovery moves—such as recapturing the $0.2432 resistance and improving RSI and OBV readings. Conversely, losing the $0.2053 support could place the token at greater risk of further losses even amid ecosystem advances.

On its third quarter of 2026 earnings call, held on Oct. 14, 2026, BlackRock (BLK +1.21%) announced quarterly net inflows of $205 billion. This capital influx pushes assets under management, the total market value of investments the firm manages for clients, to $15.5 trillion. Expanding beyond traditional index funds into private credit and infrastructure creates durable recurring fees across changing market environments. Three takeaways from the call highlight how this strategy powers long-term growth.

1. Private Markets Expand Into Artificial Intelligence InfrastructureManagement is positioning the firm at the intersection of private credit and technology infrastructure by financing massive data center builds. Integrating Global Infrastructure Partners (GIP), an infrastructure investment manager, and HPS Investment Partners, a private credit firm, gives the company full capability across corporate debt and equity structures.

We partnered with Meta on the financing of its planned $14 billion data center in Texas, bringing together infrastructure investments from GIP, private financing capabilities from HPS.
-- Laurence D. Fink, Chairman and Chief Executive Officer2. Organic Base Fee Growth Accelerates Across Asset ClassesOrganic base fee growth, which measures recurring fee revenue earned from client net inflows excluding market moves, reached 11% in the quarter. Scaling higher-fee categories like private markets and technology services keeps revenue growing even when underlying equity markets fluctuate.

Third quarter organic base fee growth was 11%. That's nine consecutive quarters at or above our 5% long-term target, and it's also the fifth consecutive quarter at or above 8%.
-- Martin S. Small, Chief Financial Officer3. Active Exchange-Traded Funds Drive Record InflowsInvestors are increasingly using exchange-traded funds, or pooled investment funds traded on public exchanges, for active management rather than simple market tracking. Expanding active offerings into exchange-traded fund structures lets the firm gather higher-margin fees while consolidating market share from traditional mutual funds.

The ETF wrapper is also evolving how investors access actively managed strategies, and iShares is leading the industry with $60 billion of active inflows in 2026, including a record $22 billion of inflows this quarter.
-- Laurence D. Fink, Chairman and Chief Executive OfficerLooking AheadCapital flows into private infrastructure and specialized fixed income are accelerating, and management isn't hiding its satisfaction about the momentum. Deep relationships with technology companies and institutional investors give the platform a distinct edge in structuring complex financing deals.

Management is watching the buildout of artificial intelligence compute financing, expanding Aladdin, the firm's investment and risk management technology platform, and maintaining pricing discipline across customized wealth portfolios.

More clients are turning to BlackRock as a destination for capital and for a partner for their growth.
-- Laurence D. Fink, Chairman and Chief Executive OfficerAs traditional banking channels face capital constraints, institutional clients are turning to private markets and technology-driven portfolio management. The firm's ability to unify public markets, private credit, and enterprise software positions it to capture long-term market share.

I am confident in the opportunities and growth ahead for BlackRock, for our clients and importantly, for our shareholders.
-- Laurence D. Fink, Chairman and Chief Executive Officer

Hedera (HBAR) reports higher TVL and TPS over 30 days, joins the UK Wholesale Digital Markets Champion Taskforce and opens its CLPR cross-ledger protocol to developers.

Hedera (@hedera) has recorded gains in network activity alongside a run of institutional and developer milestones. Total value locked (TVL) on the network reached $33.2 million, up 12.3% over 30 days, while transactions per second (TPS) rose 168.37% over the same period, based on recent Token Relations data.

Institutional steps for Hedera and $HBARHedera has become part of the UK's Wholesale Digital Markets Champion Taskforce. The taskforce is led by Christopher Woolard CBE and supported by HM Treasury, and focuses on interoperability and settlement finality in tokenized repos , according to Coinfomania. Other priorities include tokenized fixed income and collateral, with interoperability across public, private and existing financial infrastructure a key theme.

The move fed into a broader institutional narrative around the token. AMBCrypto noted that news of the taskforce seat came as Hedera was strengthening the institutional adoption narrative during a sharp rally in $HBAR in late September.

CLPR goes open sourceOn the technical side, Hedera has made its CLPR cross-ledger protocol open source through Linux Foundation Decentralized Trust (LFDT) Labs. According to Hedera, CLPR (pronounced "clipper") is the bridgeless Cross-Ledger Protocol in development by Hashgraph, contributed to LFDT as a new lab on 24 September.

The design aims to remove the need for bridges. CLPR uses state proofs to allow ledgers to verify each other's states directly, with no intermediaries in between. That matters because bridges and wrapped assets have been a weak point for the sector. Genfinity, citing industry trackers, reported that bridge incidents have cost roughly $329 million across eight attacks this year .

Alongside the contribution, Hashgraph opened a three-phase Cross-Ledger Early Adopter Program focused on cross-border payments and in-flight FX, cross-ledger settlement, and collateral mobility. The code now sits in LFDT's repositories, where developers can review it and contribute before it reaches top-level project status.

Application layer and developer toolingIn the application category, HashPack and SODAX are working to widen access to tokenized assets. Additional SDK functionality and updated atomic batch rules were also among the recent developer-side updates.

Taken together, the data points to rising on-chain activity, a clearer institutional footprint in the UK and an open-source push on interoperability. TVL of $33.2 million remains modest in absolute terms, so the next test will be whether these initiatives translate into sustained usage.

Sources:

Hedera: Hedera Contributes Hashgraph-Developed CLPR to LFDT LabsCoinfomania: Hedera Joins UK's Wholesale Digital Markets TaskforceGenfinity: Hedera Contributes Bridgeless CLPR Protocol to LFDT

Changpeng Zhao wants one thing on the record: he did not get Solana’s Shanghai ad pulled.

The Binance founder said on X that the advertisement on the city’s Bund came down within 10 minutes of appearing. He says that happened before he had even seen it. His post praising Solana followed later.

A celebration, then a crackdown
On October 15, 2026, CZ publicly applauded Solana’s new Shanghai office and its skyline advertising in the city. He framed the move as a meaningful step forward for the blockchain industry as a whole. He also set it against what BNB Chain had accomplished, a notable gesture of goodwill toward a rival ecosystem.

On October 16, 2026, Solana’s Accelerate China event at the Shangri-La hotel in Shanghai was postponed after police showed up. Attendees reported being kept outside the venue for more than an hour.

Organizers attributed the delay to “last-minute logistical considerations.” They did not elaborate on what, if anything, had passed between them and the authorities.

Speculation filled the gap. The theory making the rounds was simple: CZ’s high-profile praise had drawn the attention of regulators. In that telling, his post triggered scrutiny that led to the ad on the Bund being taken down just 10 minutes after it went up.

CZ’s version of the timeline
CZ rejected that account directly. His argument rests on sequencing.

By his account, the ad was already gone within 10 minutes of being displayed. He says he did not see it until much later. According to the research timeline, his social media post came 12 to 24 hours after the ad was removed.

CZ also pointed to China’s strict real-time content monitoring. His point was that the ad’s rapid removal fits a system built to catch this kind of material quickly, with or without a nudge from a celebrity founder on X.

China’s long, complicated relationship with crypto
China has kept its ban on crypto trading in place since 2021. At the same time, the country continues to allow blockchain development.

This is also not Solana’s first rough experience in mainland China. The postponement marked the second time in a year that a Solana event in the country was disrupted. The earlier incident took place in Shenzhen in 2025.

What this means for Solana and foreign crypto projects
For Solana, the immediate cost is reputational and logistical. A postponed flagship event and a vanished billboard are not the launch most teams envision for a new office.

CZ’s role here is interesting on its own terms. He offered public support to a competing chain, then had to spend time explaining that the support did not backfire.

The near-term reality is a canceled ad and a delayed conference.

What to watch next is fairly straightforward. Will Solana reschedule Accelerate China, and under what terms? Will organizers say more about what the authorities raised?

Disclosure: This article was edited by John Chen. For more information on how we create and review content, see our Editorial Policy.

solana coin

Solana’s blockchain network is set to enhance its transaction processing capabilities, according to a recent update from Grayscale. The network currently processes approximately 1,400 transactions per second and is anticipated to reduce transaction finality to 150 milliseconds following an upcoming upgrade. This development, known as Alpenglow, aims to improve Solana’s efficiency without altering its transaction execution or fee structure. The news has been circulating among market participants, suggesting a potential positive impact on Solana’s market perception and price trajectory.

Key Takeaways

Market activity suggests participants view Solana’s transaction speed improvement as potentially supportive of increased price expectations.
The upgrade, Alpenglow, aims to drastically reduce transaction finality time, which could attract more users and bolster network utility.
Current market pricing indicates a moderate probability of Solana achieving higher price targets in the near term.

What to Watch
Observers should monitor the successful activation of the Alpenglow upgrade and its impact on Solana’s performance metrics. Any delays or issues could affect market sentiment and pricing scenarios. Additionally, the broader cryptocurrency market conditions and regulatory developments will play a crucial role in shaping Solana’s price movements in the coming weeks. Markets will be particularly attentive to any announcements from key actors such as Solana Labs and potential regulatory changes from the U.S. Securities and Exchange Commission.

Term Structure

Contract
Odds
Δ since publish
Volume 24h

November 1 2026
0.8%
—
—
View market →

November 1 2026
4%
—
—
View market →

November 1 2026
24.5%
—
—
View market →

November 1 2026
6.9%
—
—
View market →

November 1 2026
0.5%
—
—
View market →

November 1 2026
0.9%
—
—
View market →

November 1 2026
1.6%
—
—
View market →

November 1 2026
2.2%
—
—
View market →

November 1 2026
1.9%
—
—
View market →

November 1 2026
0.1%
—
—
View market →

November 1 2026
0.1%
—
—
View market →

November 1 2026
9%
—
—
View market →

November 1 2026
0.4%
—
—
View market →

November 1 2026
2.5%
—
—
View market →

November 1 2026
73.5%
—
—
View market →

Pentiv, the new brand of Pineapple Financial, plans to tokenize its $10 billion real estate portfolio on Injective and run agentic operations onchain with $INJ.

Pentiv (@pentivhq) plans to bring its entire $10 billion real estate portfolio onchain through Injective (@injective). The company also intends to move its agentic operations onchain using $INJ. Injective says the plan marks progress toward greater institutional adoption. No rollout timeline has been announced.

What Pentiv plans to tokenizePentiv is the new operating brand of Pineapple Financial, according to CoinGabbar, which cites an October 15 filing. The same report notes the corporate rename still needs shareholder approval.

The "real estate portfolio" refers to mortgages rather than physical buildings. Pineapple Financial, listed on the NYSE American under the ticker PAPL, has already migrated more than $1 billion worth of residential mortgage records onto Injective, according to Crypto Briefing. The company has disclosed plans to eventually move its entire historical portfolio, which includes more than 29,000 funded mortgages valued at upwards of $10 billion.

The records are not new securities. Reporting from GlobalCrypto notes that the blockchain records provide an onchain representation connected to the underlying loan files, and do not themselves transfer ownership of the mortgages. The $10 billion figure therefore describes the scale of the migration ambition, not newly deposited trading liquidity, as Coindoo points out.

Crypto Briefing also reports that Pineapple holds a treasury position of around $100 million in $INJ, the native token of the Injective network.

Injective's institutional pushThe announcement adds to a series of institution-focused moves by Injective. The network's institutional arm is now an SEC registered transfer agent, according to Injective's own blog. The registration lets it maintain ownership records and process changes to them within the federal framework for securities markets.

Markets have noticed. KuCoin News reported that $INJ reached $9.16 on October 16, 2026, after a 23% single-day gain, with the token up nearly 70% over the past month. That report links the rally to several factors, including ETF filings and the Pentiv news, so the price move cannot be attributed to the tokenization plan alone.

Details on timing, the scope of each phase and how agentic operations would run onchain have not been disclosed. Until they are, the plan remains an intention rather than a completed migration.

Sources:

CoinGabbar: Injective leads major blockchains, latest revenue dataCrypto Briefing: Injective tokenizes over $1B in real estate mortgagesInjective: SEC registered transfer agent announcement

On its third-quarter 2026 earnings call, held on Oct. 14, 2026, Fastenal (FAST +1.27%) announced that sales grew 15.5%, while earnings grew faster than sales. Market share gains in large-account contracts are driving durable operating leverage for the industrial distributor. Three takeaways from the call highlight how this model compounds.

Contract customers under multi-site supply agreements now represent over three-quarters of net sales. Fastenal is expanding daily sales with these larger sites faster than the broader industrial market.

Contract customers now represent over 76% of sales, and their daily sales grew 18.8%.
-- Jeffery Watts, President and Chief Executive Officer2. Digital Replenishment Technology Deepens Customer RetentionThe company continues to deploy Fastenal Managed Inventory (FMI), its digital vending and automated bin technology that streamlines customer supply chains. Moving customers to automated ordering embeds Fastenal into daily plant operations and improves fulfillment efficiency.

We need to keep moving customers toward technology-enabled replenishment because it improves service, it strengthens the relationship, and it creates efficiency for both sides.
-- Jeffery Watts, President and Chief Executive Officer3. Workflow Automation Generates Operating Expense LeverageSelling, general, and administrative (SG&A) operating expenses dropped as a percentage of sales because headcount grew less than 1% during the quarter. Specialized digital tools and branch automation allow local teams to manage larger accounts without adding extra personnel.

This reflects productivity, role specialization and the benefits of technology and automation.
-- Max Tunnicliff, Executive Vice President and Chief Financial OfficerLooking AheadIndustrial demand is expanding across heavy manufacturing and data center build-outs, and management isn't hiding its satisfaction with top-line momentum.

Industrial conditions improved further in the third quarter.
-- Max Tunnicliff, Executive Vice President and Chief Financial OfficerFastenal holds structural advantages in its captive delivery fleet, on-site inventory hubs, and digital integration tools. Management continues to focus on price/cost neutrality to balance pricing adjustments against product inflation.

New customer wins create embedded spend, technology deepens those relationships and our scale allows us to grow profitably while continuing to invest.
-- Jeffery Watts, President and Chief Executive OfficerThis article was created using Large Language Models (LLMs) based on The Motley Fool's insights and investing approach. It has been reviewed by our AI quality control systems. Since LLMs cannot (currently) own stocks, it has no positions in any of the stocks mentioned. The Motley Fool has positions in and recommends Fastenal. The Motley Fool has a disclosure policy.

In the latest trading session, Crocs (CROX - Free Report) closed at $123.23, marking a -1.23% move from the previous day. This change lagged the S&P 500's daily loss of 1.09%. On the other hand, the Dow registered a loss of 0.34%, and the technology-centric Nasdaq decreased by 2.15%.

The footwear company's shares have seen an increase of 1.44% over the last month, surpassing the Consumer Discretionary sector's gain of 0.95% and falling behind the S&P 500's gain of 2.44%.

Analysts and investors alike will be keeping a close eye on the performance of Crocs in its upcoming earnings disclosure. The company's earnings report is set to go public on October 29, 2026. The company is expected to report EPS of $3.3, up 13.01% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $1 billion, indicating a 0.72% upward movement from the same quarter last year.

For the full year, the Zacks Consensus Estimates project earnings of $13.95 per share and a revenue of $4.11 billion, demonstrating changes of +11.51% and +1.62%, respectively, from the preceding year.

Investors should also pay attention to any latest changes in analyst estimates for Crocs. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Right now, Crocs possesses a Zacks Rank of #3 (Hold).

In the context of valuation, Crocs is at present trading with a Forward P/E ratio of 8.94. This valuation marks a discount compared to its industry average Forward P/E of 16.44.

We can also see that CROX currently has a PEG ratio of 1.04. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The average PEG ratio for the Textile - Apparel industry stood at 1.96 at the close of the market yesterday.

The Textile - Apparel industry is part of the Consumer Discretionary sector. Currently, this industry holds a Zacks Industry Rank of 202, positioning it in the bottom 18% of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

-

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into MongoDB, Inc. (NasdaqGM: MDB).

According to a securities class action complaint filed against the Company, in the first quarter of fiscal year 2024, in an effort to sustain MongoDB’s rapid growth, the Company implemented a new go-to-market strategy that eliminated sales incentives for obtaining one-year commitments from customers. The complaint alleges that this change created the illusion of sustainable growth by boosting short-term customer and workload acquisitions that had little long-term growth potential, because less information about customers’ prospective consumption was gathered during contract negotiations. Then, on May 30, 2024, despite the Company’s allegedly positive statements about its growth prospects, MongoDB released its first quarter fiscal year 2025 results and lowered its fiscal year 2025 guidance, admitting that it had “lost some focus on workload growth potential” and that workloads acquired in fiscal year 2024 were growing more slowly than expected.

Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period, violating federal securities laws. Recently, the Court presiding over the case denied the defendants’ motion to dismiss the case in part, allowing the case to continue.

KSF’s investigation is focusing on whether MongoDB’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of MongoDB shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-538-3606 or email KSF Managing Partner Lewis Kahn ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgm-mdb/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

More News From Kahn Swick & Foti, LLC

Back to Newsroom

 | Source: Dime Commercial Bancshares, Inc.

HAUPPAUGE, N.Y., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Dime Commercial Bancshares, Inc. (NYSE: DCOM) (the "Company") today announced that the Company expects to release its earnings for the quarter ended September 30, 2026, before the open of the U.S. equity markets on Tuesday, October 20, 2026. The Company will conduct a conference call at 8:30 a.m. (ET) on Tuesday, October 20, 2026, during which President and Chief Executive Officer (“CEO”), Stuart Lubow, will discuss the Company’s third quarter financial performance. There will be a question-and-answer period after the CEO remarks.

Participants may access the conference call via webcast using this link: Webcast Link Here. To participate via telephone, please register in advance using this Registration Link. Upon registration, all telephone participants will receive a one-time confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used to access the call. All participants are encouraged to dial-in 10 minutes prior to the start time.

A replay of the conference call and webcast will be available on-demand which will be available for 12 months.

ABOUT DIME COMMERCIAL BANCSHARES, INC.

Dime Commercial Bancshares, Inc. is the holding company for Dime Commercial Bank, a New York State-chartered trust company with approximately $15 billion in assets and the number one deposit market share on Greater Long Island (1).

Investor Relations Contact:
Avinash Reddy
Senior Executive Vice President – Chief Operating Officer and Chief Financial Officer
Phone: 718-782-6200; Ext. 5909
Email: [email protected]

¹ Aggregate deposit market share for Kings, Queens, Nassau & Suffolk counties for commercial banks with less than $20 billion in assets.

FORWARD-LOOKING STATEMENTS
Statements contained in this news release that are not historical facts are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties which could cause actual results to differ materially from those currently anticipated.

In the latest close session, Alibaba (BABA - Free Report) was down 1.82% at $109.11. The stock trailed the S&P 500, which registered a daily loss of 1.09%. Meanwhile, the Dow experienced a drop of 0.34%, and the technology-dominated Nasdaq saw a decrease of 2.15%.

Prior to today's trading, shares of the online retailer had gained 2.39% lagged the Retail-Wholesale sector's gain of 3.71% and the S&P 500's gain of 2.44%.

Investors will be eagerly watching for the performance of Alibaba in its upcoming earnings disclosure. The company is predicted to post an EPS of $1.46, indicating a 139.34% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $40.35 billion, up 15.93% from the year-ago period.

For the full year, the Zacks Consensus Estimates project earnings of $6.35 per share and a revenue of $166.47 billion, demonstrating changes of +63.24% and +14.5%, respectively, from the preceding year.

It's also important for investors to be aware of any recent modifications to analyst estimates for Alibaba. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 3.43% lower. At present, Alibaba boasts a Zacks Rank of #3 (Hold).

Looking at its valuation, Alibaba is holding a Forward P/E ratio of 17.51. This indicates a premium in contrast to its industry's Forward P/E of 15.65.

Investors should also note that BABA has a PEG ratio of 1.31 right now. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. BABA's industry had an average PEG ratio of 1.25 as of yesterday's close.

The Internet - Commerce industry is part of the Retail-Wholesale sector. At present, this industry carries a Zacks Industry Rank of 174, placing it within the bottom 30% of over 250 industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

Bitcoin turned lower in late morning trade, retesting the $80,000 threshold heading into the weekend. The flagship cryptocurrency is down 1.3% to $80,970 Friday afternoon, according to pricing data from LSEG. The cryptocurrency had rallied along with the stock markets in morning trade, but succumbed to continued weakness seen in tech and AI stocks, following the 2.4% slide seen on the Nasdaq.

Bond yields turned higher in the afternoon, this after the Treasury Department passed on an opportunity to send a strong signal that it is considering reducing the sizes of bond auctions. Higher yields have been a pressure point for cryptocurrencies and general commodities, with investors cautious about engaging with what they perceive as "riskier" assets.

Crypto assets were supported in morning trade by dimming expectations for a near-term Federal Reserve rate hike. Fed Chairman Kevin Warsh avoided a clearly hawkish or dovish tone during a moderated conversation at the International Monetary Fund meetings in Bangkok. But for bitcoin, lacking demand for tokens on the spot market is a fundamental problem that hasn't gone away.

"The demand picture has not improved," said Colin Basco, a senior quantitative analyst with Coinbase Institutional. Basco attributes the upward movement seen in bitcoin earlier in the week to trading by leveraged long positions, as opposed to spot demand among investors. Net flows in and out of bitcoin ETFs, considered a metric of interest in the cryptocurrency among fund managers, have slid back into being more negative than positive for the week.

Through Thursday, bitcoin ETFs recorded a net outflow of $146 million, according to data from Coinglass. At the same time, analysts say that bitcoin's relative strength versus AI stocks this week is reason for optimism. Bitcoin shed roughly 3% this week, while the iShares Semiconductor ETF slipped 9%. Write to Kirk Maltais at [email protected] (END) Dow Jones Newswires 10-16-26 1543ET Copyright (c) 2026 Dow Jones & Company, Inc.

Key Takeaways ISRG, the undisputed leader in surgical robotics, is down 30% from its 2025 highs.
The Zacks Rank #2 (Buy) stock is poised for a technical breakout heading into its Q3 earnings release.
Intuitive's pristine debt-free balance sheet empowers it to adapt and expand.
Intuitive Surgical, Inc. (ISRG - Free Report) , the medical technology giant and the undisputed leader in surgical robotics, has fallen 30% from its early 2025 highs.

The selloff and its strong fundamentals, including a double-digit earnings and revenue growth outlook and impressive free cash flow expansion, make ISRG stock a great buy-and-hold candidate right now, especially as Wall Street keeps selling AI stocks.

ISRG stock surged off its recent lows heading into its Q3 earnings release that’s due out after the closing bell on Tuesday, October 20.

Intuitive Surgical stock earns a Zacks Rank #2 (Buy) and looks poised for a potential technical breakout as it overtakes vital long-term levels.

Image Source: Zacks Investment Research

The firm’s pristine debt-free balance sheet empowers Intuitive Surgical to adapt and expand into any number of growth areas.

All in, investors looking to diversify beyond tumbling AI stocks should consider buying the da Vinci robotic surgery systems maker for ~40% upside if it ever returns to its all-time highs.

Looking for S&P 500 Stocks to Buy On the Dip in Q3 Earnings Season? Buy ISRGIntuitive Surgical helped kick off the Sci-Fi age of healthcare when its da Vinci Surgical System was first cleared by the FDA in 1997 to assist in surgery and to perform actual surgery in 2000. Since then, its da Vinci robotic surgery systems have become integral throughout an array of procedures across urology, general surgery, gynecology, and beyond.

ISRG’s robots give surgeons better control, vision, and precision through small incisions, which can mean less pain, smaller scars, and faster recovery for patients compared with traditional open surgery.

The firm boasts that its technologies have performed 20.4 million+ procedures since it launched (as of Dec. 2025), including 3.2 million+ procedures performed on Intuitive systems in 2025.

Image Source: Zacks Investment Research

The S&P 500 medical technology company is making progress in vital surgical areas such as Thoracic (chest/lung surgery), Cardiac, Head and neck, and more.

The company also makes a robotic system for lung biopsies (not surgery) called the Ion. It helps doctors reach and sample small, hard-to-reach nodules deep in the lungs to check for cancer or other issues.

Intuitive Surgical’s rise sparked competition from Medtronic, Johnson & Johnson (JNJ - Free Report) , and others. But its growth outlook remains impressive after 25 years of expansion, and its offerings are only gaining in popularity as the healthcare world races to embrace as much cutting-edge technology as possible. 

Buy ISRG Stock for Earnings and Sales GrowthISRG more than doubled its revenue between 2020 and 2025. It grew its sales by 21% in 2025, marking its strongest YoY expansion since 2021. The surgical robotics firm also doubled its GAAP earnings between the pre-Covid period in 2019 and 2025, boosted by 29% average expansion over the past three years.

In the near term, Intuitive Surgical is projected to grow its Q3 revenue by 15% to $2.88 billion. The company is projected to grow its adjusted quarterly earnings by 9% YoY to $2.61 a share.

ISRG beat our Zacks bottom-line estimate by an average of 17% in the past four quarters. Its upbeat EPS revisions for 2027 help it earn a Zacks Rank #2 (Buy) right now.

Image Source: Zacks Investment Research

It is projected to grow its revenue by 17% in 2026 and 13% next year to reach $13.21 billion, doubling 2022’s total in the process.

ISRG is expected to grow its adjusted earnings by over 20% in 2026 and 12% next year. The chart below showcases that its long-term earnings growth outlook over the next several years remains impressive.

Image Source: Zacks Investment Research

Why ISRG is One of the Best Stocks to Buy Now for Big UpsideISRG stock has climbed by a mind-blowing ~20,800% in the past 25 years, including a ~790% charge in the last 15 to crush its industry’s 300%.

Yet it has lagged the S&P 500 over the last five years on the back of its ~30% fall from its early 2025 highs.

This backdrop alone means that Intuitive Surgical offers roughly 43% upside if it ever returns to its all-time highs. The stock already climbed 30% from its July lows after buyers stepped in and held their ground near its previous 2021 highs.

ISRG is on the cusp of overtaking its 200-day. More importantly, Intuitive Surgical stock is back above its critical long-term 200-week moving average.

Image Source: Zacks Investment Research

One thing holding the stock back appears to be its valuation, with it trading at 43.7X forward 12-month earnings. This marks a huge premium compared to its industry’s 27.9X. But it has crushed its peers over the last 10 years, up ~470% vs. 112%. Plus, ISRG is trading at a 53% discount to its highs.

If Wall Street continues to reject its valuation levels as its growth slows, Intuitive Surgical could easily start paying a dividend to reward investors, given its debt-free balance sheet and growing cash position.

Over the past four years, a $1,000 investment in TSMC (TSM -2.28%), the world's largest contract chipmaker, would have grown to about $4,540. That multibagger gain was primarily driven by the rapid growth of the cloud infrastructure and AI markets.

Could a fresh $1,000 investment in TSMC grow to more than $4,500 again by the end of the decade? Let's review its catalysts, challenges, and valuations to see if it's possible.

Image source: Getty Images.

Understanding TSMC's core advantages TSMC manufactures the world's smallest, densest, and most power-efficient chips for fabless chipmakers like Nvidia (NVDA -1.43%), AMD, and Broadcom. To maintain its lead over other foundries, TSMC purchases more extreme ultraviolet (EUV) lithography systems -- which are required for optically etching tiny circuit patterns onto silicon wafers -- from ASML (ASML -0.96%) than any other foundry.

Once a fabless chipmaker is locked into TSMC's manufacturing services, the astronomical switching costs prevent it from moving to a competing foundry such as Samsung or Intel (INTC -5.79%). TSMC also offers a higher yield (the percentage of functional chips per wafer) than other foundries. So while TSMC's competitors might offer lower manufacturing costs per wafer, their lower yields and tighter production bottlenecks can easily offset those savings.

TSM Taiwan Semiconductor Manufacturing$412.61-$9.64 (-2.28%)

NYSE · As of 4:00 PM ET 10/16/26

TSMC's scale enables it to push ASML's current-gen "low-NA" EUV systems to their theoretical limits (to 1.4nm) before it needs to buy ASML's pricier "high-NA" EUV systems to produce even smaller chips. By comparison, Intel is making the leap to high-NA much earlier than TSMC -- but that expansion will be costly because those systems cost about twice as much as low-NA systems. By waiting until the early 2030s to ramp up its purchases of high-NA EUV systems, TSMC can wait for the technology to mature and become cheaper before making that leap.

In the third quarter of 2026, TSMC generated 68% of its revenue from the high-performance computing (HPC) market -- which includes Nvidia's data center GPUs and Broadcom's custom application-specific integrated circuits (ASICs) for hyperscalers.

That segment's revenue surged 22% sequentially in the third quarter, accelerating from 20% sequential growth in the first and second quarters. That acceleration should continue as long as more companies upgrade their cloud and AI data centers. It also generated a third of its revenue from its smallest 3nm chips -- which include Nvidia's Vera Rubin (Vera CPU and Rubin GPU) chips and the base die of the latest high-bandwidth memory (HBM) chips.

How much bigger could TSMC grow? Back in January, TSMC expected its revenue to grow in the mid-to-high 20% range in USD terms for the full year. But it raised its outlook to over 30% growth in its first-quarter report, just over 40% in its second-quarter report, and 44% in its third-quarter report. It kept raising its guidance to reflect the feverish growth of the generative AI market.

For 2026, analysts expect its revenue and EPS to rise 46% and 66%, respectively, in TWD terms. From 2026 to 2028, they expect its revenue and EPS to grow at CAGRs of 32% and 31%, respectively. Yet TSMC's stock still looks cheap at 16 times next year's earnings.

If TSMC matches analysts' expectations through 2028, grows its EPS at a 25% CAGR for the next three years, and trades at 20 times forward earnings by late 2030, its stock could turn $1,000 into over $3,000. That wouldn't match its performance over the past four years, but it would still beat the S&P 500's (^GSPC -1.09%) average annual total return of about 10%.

TSMC might face unpredictable challenges over the next few years, including conflicts between Taiwan and China, the costly construction of its overseas plants (especially in the U.S.), and an abrupt slowdown in AI spending. But over the long term, it will likely remain a linchpin of the global semiconductor market -- and it should generate impressive gains for its patient investors.

Leo Sun has positions in ASML. The Motley Fool has positions in and recommends ASML, Advanced Micro Devices, Broadcom, Intel, Nvidia, and Taiwan Semiconductor Manufacturing. The Motley Fool has a disclosure policy.

OPEN Opendoor Technologies$2.12-$0.21 (-8.84%)

NASDAQ · As of 4:00 PM ET 10/16/26

Opendoor Technologies (OPEN -8.84%), a digital home buying, selling, and settlement platform, closed at $2.12, down 8.84% on Oct. 16, 2026. Friday's slide followed reports of fresh 52-week lows and higher debt costs, while investors are watching early November earnings for guidance, liquidity, and margin trends.

Trading volume reached 64.6 million shares, coming in about 53% above its three-month average of 42.1 million shares. Opendoor Technologies IPO'd in 2020 and has fallen 80% since going public.

How the markets moved todayS&P 500 (SNPINDEX: ^GSPC) closed at 7,659, down 1.09%, while the Nasdaq Composite (NASDAQINDEX: ^IXIC) finished at 26,140, down 2.14%. Among U.S. online residential real estate transactions and iBuying peers, Zillow Group (ZG -1.70%) closed at $31.88, down 1.70%, as housing and rate sensitivity kept the sector under pressure.

What this means for investorsOpendoor Technologies stock fell today, Oct. 16, as shares still felt the sting of this week’s plunge to a historical all-time low of $1.93 per share during intraday trading on Oct. 15. The stock had recovered from the low as a sharp drop in the 10-year Treasury yield fueled a small rally. That trend reversed today as a sluggish housing market battling rising interest rates kept Wall Street investors concerned about the company and the real estate sector in general.

Last week, Opendoor said its home-loan unit exited beta and added fixed and adjustable mortgages, which could broaden the platform and support transaction volume. The new offering is intended to streamline the homebuying process for consumers with loan pre-qualification happening in minutes.

The company is working to transform its business amid declining sales. In the second quarter, Opendoor reported revenue of $883 million, a massive drop from 2025's $1.6 billion. Adding to the dismal picture, its costs rose, resulting in a Q2 net loss of $162 million, up from a loss of $29 million in the prior year. That said, Opendoor forecasted Q3 sales to grow 20% year over year. Investors will be closely watching the next earnings report to see if Opendoor can deliver.